Hemostemix Inc. is a clinical-stage biotechnology company focused on commercializing its autologous cell-based therapy, ACP-01, as a therpy for ischemic and cardiovascular conditions. The company conducts and supports investigator-led clinical research, physician education, and scientific collaboration centered on regenerative mechanisms such as angiogenesis.